再颁专利
- 专利标题： Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
- 专利标题（中）： 喹喔啉基大环丙型肝炎丝氨酸蛋白酶抑制剂
-
申请号： US12069553申请日： 2008-02-11
-
公开(公告)号： USRE42375E1公开(公告)日： 2011-05-17
- 发明人: Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
- 申请人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
- 申请人地址： US MA Watertown
- 专利权人： Enanta Pharmaceuticals, Inc.
- 当前专利权人： Enanta Pharmaceuticals, Inc.
- 当前专利权人地址： US MA Watertown
- 代理机构： Elmore Patent Law Group, P.C.
- 代理商 Carolyn S. Elmore, Esq.; Edgar W. Harlan
- 主分类号： C07D401/12
- IPC分类号： C07D401/12 ; C07D409/14 ; A61K31/38 ; A61K31/395 ; A61P31/12
摘要：
The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
信息查询
